본문으로 건너뛰기
← 뒤로

Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.

Gastroenterology clinics of North America 2026 Vol.55(1) p. 1-19

Wang F, Kahn A, Kisiel JB, Iyer PG

📝 환자 설명용 한 줄

The increasing burden of esophageal adenocarcinoma (EAC) has driven efforts to improve early detection and risk stratification.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Wang F, Kahn A, et al. (2026). Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.. Gastroenterology clinics of North America, 55(1), 1-19. https://doi.org/10.1016/j.gtc.2025.09.001
MLA Wang F, et al.. "Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.." Gastroenterology clinics of North America, vol. 55, no. 1, 2026, pp. 1-19.
PMID 41581944

Abstract

The increasing burden of esophageal adenocarcinoma (EAC) has driven efforts to improve early detection and risk stratification. Barrett's esophagus (BE), the only known precursor to EAC, presents an opportunity for screening and surveillance. This article highlights major advances in molecular biomarkers for BE, such as the Cytosponge-TFF3 test, methylated DNA markers, p53, aneuploidy, and other emerging biomarkers. Their integration into clinical practice may transform esophageal cancer detection and prevention by enabling precision screening and surveillance and by broadening access to care.

MeSH Terms

Humans; Barrett Esophagus; Esophageal Neoplasms; Prognosis; Adenocarcinoma; Biomarkers, Tumor; DNA Methylation; Precancerous Conditions; Biomarkers; Early Detection of Cancer; Aneuploidy

같은 제1저자의 인용 많은 논문 (5)